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Abstract
ThepossibleeffectofantihypertensivetherapyonAlzheimer’sdisease(AD)hasbeen
studied, and angiotensin II receptor blockers (ARBs) have been suggested to exert
an effect on cognitive decline. The purpose of this study is to clarify the functional
effects of telmisartan, a long-acting ARB, on AD brain using prospective longitudi-
nal 18F-ﬂuorodeoxyglucosepositronemissiontomography(FDG-PET)studies.For
this purpose, brain glucose metabolism of four hypertensive patients with AD was
examined with FDG-PET before and after administration of telmisartan. Studied
subjects underwent three FDG-PET studies at intervals of 12 weeks. Antihyper-
tensive treatment except for telmisartan was started after the ﬁrst FDG-PET and
continued for 24 weeks. Then 40–80 mg of telmisartan was added after the second
FDG-PET and continued for 12 weeks.Glucose metabolism was signiﬁcantly de-
creasedduringtheﬁrst12weekswithouttelmisartanuseatanarea(−10,21,−22,x,
y, z; Z = 3.56) caudal to the left rectal gyrus and the olfactory sulcus corresponding
to the left olfactory tract. In contrast, the introduction of telmisartan during the
following 12 weeks preserved glucose metabolism at areas (5, 19, −20, x, y, z; Z =
3.09;6,19,−22,x,y,z;Z=2.88)caudaltothebilateralrectalgyriandolfactorysulci
corresponding to the bilateral olfactory tracts. No areas showed decreased glucose
metabolism after the introduction of telmisartan. In AD, amyloid-β deposition is
observed in the anterior olfactory nucleus (AON) of the olfactory tract. Glucose
metabolism in AON may be progressively decreased and preserved by telmisartan.
Introduction
Many risk factors for dementia have been epidemiologically
investigatedwiththehopeofpreventingordelayingtheonset
of Alzheimer’s disease (AD; Korczyn and Vakhapova 2007).
Hypertension is linked to AD along with smoking, diabetes
mellitus, and hypercholesterolemia (Papademetriou 2005;
Kehoe and Wilcock 2007). The possible effect of antihyper-
tensive therapy on AD has been studied, and it is suggested
that angiotensin-converting enzyme (ACE) inhibitors and
angiotensin II receptor blockers (ARBs) exert a greater effect
oncognitivedeclinethanotherantihypertensivemedications
(Gard 2002, 2004).
Telmisartan is a long-acting ARB that is effective for early
hypertension. It has in addition peroxisome proliferator-
activated receptor gamma (PPARγ) agonist effects (Benson
et al. 2004; Lacourcire et al. 2004). Henka et al. (2005) re-
ported that treatment with the PPARγ agonist pioglitazone
reduces soluble amyloid-β (Aβ)1–42 peptide in mice. It has
been shown that mRNA and protein levels of β-secretase
or β-site amyloid precursor protein cleaving enzyme is re-
pressed by pioglitazone resulting in reduction of Aβ1–42
(Sastre et al. 2006). Clinically, PPARγ agonists have been re-
ported to act as insulin sensitizers, and to improve cognition
and memory in AD patients (Watson et al. 2005; Landreth
2007). Mogi et al (2008) showed that telmisartan prevented
cognitive decline partly due to PPARγ activation. Recently
PPARγ activationinthebrainhasbeenhighlightedtoprevent
AD via enhancement of Aβ clearance (Camacho et al. 2004)
andantiinﬂammatoryeffectsinneurons(Luna–Medinaetal.
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2005),endothelialcells(Wangetal.2002),astrocytesandmi-
croglia (Klotz et al. 2003), and an increase in neural stem cell
proliferation (Wada et al. 2006; Morales–Garcia et al. 2010).
Fromtheseﬁndings,itishopedthattreatmentofbloodpres-
sure (BP) with telmisartan may mitigate the cognitive de-
cline in AD. The purpose of the present study is to clarify the
functional effects of telmisartan on AD brain using prospec-
tive longitudinal 18F-ﬂuorodeoxyglucose positron emission
tomography (FDG-PET) studies. In the revised NINCDS-
ADRDA criteria, FDG-PET is dealt with as a topographical
marker and is described to be more useful than pathological
markers when the ﬁrst cognitive symptoms are manifest in
preclinical AD patients (Dubois et al. 2010).
Materials and Methods
Subjects
Among hypertensive outpatients with memory impairment
with systolic blood pressure (SBP) of ≥140 mmHg or di-
astolic blood pressure (DBP) of 90 mmHg in the Depart-
ment of Neurology of Saitama Medical University Hospital,
those who were clinically diagnosed with AD according to
revised NINCDS-ADRDA criteria, were recruited (Dubois
et al. 2010). Patients who met the following criteria were
excluded: (1) history of allergy to ARB; (2) SBP of ≥160
mmHg or DBP of ≥100 mmHg; (3) pregnancy; (4) severe
biliary excretion dysfunction with serum total bilirubin con-
centrationabove2.0mg/dL;(5)severeliverdysfunctionwith
serum asparatate aminotransferase (AST) or alanine amino-
transferase (ALT) above 100IU/L; (6) severe renal dysfunc-
tion with serum Cr level above 3.0 mg/dL; (7) hyperkalemia;
(8) continuous administration of ARB, ACE inhibitor, or pi-
oglitazone; (9) other conditions deemed inappropriate for
thepurposesofthisstudybytheinvestigators.Sevenpatients
whometthesecriteriawereenrolled.FDG-PETﬁndingsofall
patients were supportive of AD. Of these seven patients, one
experienceddigestivetracthemorrhageduringthefollow-up
studies and two refused to continue to participate. Finally
four AD patients, two men and two women, aged from 70
to 77 years, ﬁnished the present longitudinal study proto-
col. At each FDG-PET study, mini-mental state examination
( M M S E )w a sa d m i n i s t e r e da n dB Pw a sm e a s u r e d .
This study was approved by the institutional review board
of Saitama Medical University International Medical Center
and Saitama Medical University Hospital, and all subjects
gave written informed consent to participate.
Study protocol
The subjects underwent three FDG-PET studies at intervals
of 12 weeks. Antihypertensive treatment except for telmisar-
tan was started immediately after the ﬁrst FDG-PET study
and continued for 24 weeks. Then 40–80 mg of telmisartan
wasaddedimmediatelyafterthesecondFDG-PETstudyand
continued for 12 weeks (Fig. 1).
FDG-PET
FDG-PET was performed in the Department of Nuclear
Medicine of Saitama Medical University International Medi-
cal Center. Before FDG-PET was performed, all subjects had
an intravenous line established. Each subject received an in-
travenous injection of 185 MBq of FDG while lying in the
supinepositionwitheyesclosedinadimlylit,quietroomand
waskeptinthesamerestingstateforatleast20minutes.Fifty
minutesaftertheinjectionofFDG,brainPETwasperformed
using PET/Computed Tomography (CT) equipment with
high spatial resolution (Biograph 6 Hi-Rez; Siemens Medical
Systems, Inc.:Suite, Washington, D.C., United States). The
combination of Fourier rebinning and the ordered subsets
expectation-maximization at iteration number 4 and subset
16, and Gaussian ﬁlter at 6-mm full width at half maximum
(FWHM) was used for PET image reconstruction. Attenua-
tion correction was performed using CT data.
Image preprocessing
All FDG-PET images were spatially normalized
using statistical parametric mapping 2 (SPM2;
http://www.ﬁl.ion.ucl.ac.uk/spm/) to a standardized
stereotactic space based on the Talairach and Tournoux
(1988) atlas, using 12-parameter linear afﬁne normalization
and a further 16 nonlinear iteration algorithms with
an original template of FDG (Sakai et al. 2006). Then,
isotropic Gaussian smoothing with 12-mm full-width at half
maximum was performed.
Figure 1. Study protocol. Subjects
underwent FDG-PET at three points: the ﬁrst
at entry into this study, the second and third
at 12 and 24 weeks after the 1st study,
respectively. Telmisartan therapy was started
immediately after the second study.
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Image analysis
Data were analyzed also using SPM2 program. The SPM2
combines the general linear model and the theory of Gaus-
sian ﬁelds to make statistical inferences about regional ef-
fects (Friston et al. 1991, 1994). To examine changes in brain
glucose metabolism during the 12 weeks without telmisar-
tan, regionally speciﬁc differences between the ﬁrst and sec-
ond FDG-PET were statistically assessed using a two-tailed
paired contrast testing for a decreased probability of glucose
metabolism. Then to examine regionally speciﬁc differences
in glucose metabolism between the two conditions, with and
without telmisartan, the ﬁrst, second, and third FDG-PET
were statistically assessed. A two-tailed contrast testing was
usedforanincreasedordecreasedprobability(multiplesub-
jects with different conditions in SPM2). To exclude time
effect in voxel intensity across three scans, the term days was
includedasanuisancecovariate.Theanalysiswasperformed
with normalization of global glucose metabolism for each
subject to the same mean value with proportional scaling to
comparetwoconditionsregardingrelativeFDGdistribution.
The gray matter threshold was set to 0.8.
The resulting set of values for each contrast constituted
a statistical parametric map of the t statistic SPM {t}.T h e
SPM {t} m a p sw e r et h e nt r a n s f o r m e dt ot h eu n i t so fn o r -
mal distribution (SPM {Z}), and height threshold was set to
P = 0.005 uncorrected for multiple comparisons with extent
thresholdto100voxels.Theseareasofsigniﬁcancewerevisu-
alizedasoverlaidonanormalizedMRimagetoobtainaclear
view of the location of the glucose metabolism changes.
Results
MMSE scores and BP are listed in Table 1. No signiﬁcant
changes in MMSE scores were observed during the time
course. SBP declined signiﬁcantly from the ﬁrst to third and
from the second to third FDG-PET. DBP declined signiﬁ-
cantly from the ﬁrst to third FDG-PET.
Glucose metabolism was signiﬁcantly decreased during
the ﬁrst 12 weeks without telmisartan at an area (−10, 21,
−22, x, y, z; Z = 3.56) caudal to the left rectal gyrus and
the olfactory sulcus corresponding to the left olfactory tract
(Fig. 2).
Incontrast,theintroductionoftelmisartanduringthefol-
lowing 12 weeks preserved glucose metabolism at areas (5,
19, −20, x, y, z; Z = 3.09; −6, 19, −22, x, y, z; Z = 2.88)
caudal to the bilateral rectal gyri and olfactory sulci corre-
sponding to the bilateral olfactory tracts (Fig. 3). No areas
showed decreased glucose metabolism after the introduction
of telmisartan.
Discussion
This short-term study showed a signiﬁcant decline and
preservation of glucose metabolism in a localized area cau-
dal to the rectal gyrus corresponding to the olfactory tract
duringtheﬁrst12weekswithouttelmisartan,andduringthe
following 12 weeks with telmisartan, respectively.
The localized area corresponding to the olfactory tract de-
tectedbystatisticalanalysisoflongitudinalFDG-PETstudies
contains the anterior olfactory nucleus (AON; Saiz–Sanchez
etal.2010).AONplaysacentralroleinhumanolfactorypro-
cessing (Price 2004; Brunjes and Kenerson 2010). Though
central olfactory connections are scarcely known in man,
AON is assumed to have connections to the piriform cortex,
anterior amygdala, periamygdaloid cortex, and the rostal en-
torhinal cortex (Price 2004). In Parkinson’s disease, Lerner
and Bagic (2008) proposed that AON is connected to the
dorsal motor nucleus of the vagus by three principal path-
ways: the stria medullaris thalami and habenular nuclei, the
Table 1. Subjects’ background, blood pressure, and cognitive state.
*P < 0.005; **P < 0.01; §P < 0.05.
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Figure 2. Statistically signiﬁcant decrease of
glucose metabolism from the ﬁrst to second
FDG-PET studies in an area caudal to the left
rectal gyrus and the olfactory sulcus
corresponding to the left olfactory tract (P <
0.005). The SPM of the t-statistics is
displayed in a standard format as a
maximum intensity projection viewed from
right-hand side and from the top and the
back (top), and as orthogonal sections
(bottom).
amygdalaandstriaterminalis,andthemedialforebrainbun-
dleandhypothalamus.Becauseofthesemanypathways,AON
is assumed to be rich in dendrites and astrocytes, resulting in
abundantglucoseconsumptioninthissmallregion(Iadecola
and Nedergaard 2007).
Hyposmia has been suggested to be a diagnostic symptom
in early AD (Djordjevic et al. 2008). Li et al. (2010) proposed
an objective way to reveal olfactory functional deﬁcits in AD
patientsusingafunctionalMRI.Olfactoryfunctionalimpair-
ment may result from early neurodegeneration of olfactory
systemsincludingAON(Pearsonetal.1985;BraakandBraak
1991; Price et al. 1991). Kovacs et al. (1999) showed that Aβ
depositionandneuroﬁbrillarytangleformationareobserved
in the olfactory bulb both in aging and AD though more fre-
quently in the latter. Moreover, Saiz-Sanchez et al. (2010)
analyzed the AON expression levels of somatostatin in AD
versus controls, and found that levels of somatostatin were
reduced in AON of AD cases compared to controls. It also
hasbeenreportedthatthereductioninsomatostatininduces
downregulation of neprylisin, a peptidase that catalyzes the
proteolytic degradation of Aβ, and that may be a trigger for
Aβ accumulation leading to late-onset sporadic AD (Saito et
al. 2005). Decreased somatostatin expression may therefore
result in Aβ accumulation. Furthermore, a reduction in the
densityofaxonswasobservedintheolfactorytractofADpa-
tients(Armstrongetal.2008).Consideringsuchinvolvement
of the olfactory system in AD (Brunjes and Kenerson 2010),
glucosemetabolisminAONmaybedecreasedmoreprogres-
sively within a short interval than in any other brain region.
Telmisartan is known to effectively reduce Aβ deposition
(Mogi et al. 2008) and to induce PPARγ activation. This
PPARγ activation has been reported to prevent brain dam-
age through an antiinﬂammatory effect, for example in en-
dothelial cells, astrocytes, and microglia (Wang et al. 2002;
Klotz et al. 2003; Camacho et al. 2004; Heneka et al. 2005;
Luna–Medina et al. 2005; Watson et al. 2005; Sastre et al.
2006; Wada et al. 2006; Landreth 2007; Mogi et al. 2008;
Morales–Garcia et al. 2010). Thus, the current study sup-
ports the contention that progressive AD pathology in AON
may be prevented by telmisartan.
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Figure 3. Statistically signiﬁcant preservation of glucose
metabolism by telmisartan from the ﬁrst and second to
third FDG-PET studies in areas caudal to the bilateral rectal
gyri and the olfactory sulci corresponding to bilateral
olfactory tracts (P < 0.005). The SPM of the t-statistics is
displayed in a standard format as a maximum intensity
projection viewed from right-hand side and from the top
and the back (top) and as orthogonal sections (bottom).
Thepresentstudyperiodmaybetooshorttodetectcogni-
tivechanges.However,thisshorttermmaynotbeinappropri-
ateto observe anyearlyeffectof telmisartanonbrainglucose
metabolism. Although a further study may be necessary in a
larger number of subjects, the current well-localized results
with statistical signiﬁcance may help to deﬁne the effect of
telmisartan on AD brain.
Conclusion
In consideration of the recent many studies on the olfac-
tory systems in AD, high-resolution FDG-PET is quite use-
ful for the functional evaluation of a small area involv-
ing AON. Telmisartan therapy may inhibit short-term de-
cline of glucose metabolism in the olfactory tract in AD
brain.
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